earnings
confidence high
sentiment neutral
materiality 0.70
Allogene expects FDA clearance for first allogeneic CAR T pivotal trial; Q2 net loss $74.8M
Allogene Therapeutics, Inc.
2022-Q2 EPS reported
-$1.09
revenue$147,000
- FDA clearance expected in coming weeks for Phase 2 pivotal trial of ALLO-501A in LBCL; would be first allogeneic CAR T pivotal trial.
- Ended Q2 2022 with $686M cash, cash equivalents and investments; net loss $74.8M ($0.52 per share).
- Full year GAAP OpEx guided to low end of $360M-$390M; cash burn ~$250M for 2022.
- CF1 manufacturing facility operational; projected capacity ~20,000 doses/year; earned LEED Gold designation.